

Validation data for RBD-LuciaV8 (B.1.617.2)

<https://www.invivogen.com/b16172-rbd-lucia>

For research use only

Version 21117-NJ

RBD-LuciaV8 (B.1.617.2) is a soluble fusion protein composed of the Spike Receptor Binding Domain (RBD) from the SARS-CoV-2 Delta variant (B.1.617.2) fused to a C-terminal Lucia luciferase reporter. This protein has been specifically designed to assess the binding affinity of anti-Spike antibodies using either ELISA (**Fig. 1**) or the solution phase assay LIPS (luciferase immunoprecipitation systems).

RBD-LuciaV8 (B.1.617.2) for a Luciferase-based ELISA

Unlike a conventional ELISA, the plate was coated overnight with an Anti-murine IgG F(ab')₂ fragment as the 'capture antibody'. InvivoGen's collection of clinically-relevant anti-spike monoclonal antibodies (mAbs) were added and the binding affinity of these mAbs to RBD-LuciaV8 (B.1.617.2) was assessed using the Lucia luciferase activity.




Figure 1: Luciferase-based ELISA using RBD-LuciaV8 (B.1.617.2). Anti-murine IgG F(ab')₂ fragment (2 µg/ml) was coated on an ELISA plate overnight. Anti-CoV2RBD-cas-mIgG2a, Anti-CoV2RBD-imd-mIgG2a, Anti-CoV2RBD-bam-mIgG2a, Anti-CoV2RBD-ete-mIgG2a, or the negative control Anti-βGal-mIgG2a, along with RBD-LuciaV8 (B.1.617.2) (1 µg/ml) were added and incubated for 2 hours at room temperature. After washing (3x times), binding affinity was assessed by measuring the activity of Lucia luciferase in the supernatant using QUANTI-Luc™. Data are shown as a fold change over no antibody.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Asia: +852 3-622-34-80

E-mail: info@invivogen.com